KR950005329A - 서방성 비경구 투여제제 및 그 제조방법 - Google Patents

서방성 비경구 투여제제 및 그 제조방법 Download PDF

Info

Publication number
KR950005329A
KR950005329A KR1019940020306A KR19940020306A KR950005329A KR 950005329 A KR950005329 A KR 950005329A KR 1019940020306 A KR1019940020306 A KR 1019940020306A KR 19940020306 A KR19940020306 A KR 19940020306A KR 950005329 A KR950005329 A KR 950005329A
Authority
KR
South Korea
Prior art keywords
sustained
release parenteral
preparation according
parenteral preparation
protein
Prior art date
Application number
KR1019940020306A
Other languages
English (en)
Other versions
KR100338400B1 (ko
Inventor
유따까 야마가따
가쓰미 이가
히로아끼 오까다
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR950005329A publication Critical patent/KR950005329A/ko
Application granted granted Critical
Publication of KR100338400B1 publication Critical patent/KR100338400B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

비경구 투여제제는 생리활성의 펩티드 또는 단백질과 포화 지방산의 폴리글리세롤 디에스테르를 함유하는 매트릭스로 구성되어 있고, 이 매트릭스는 실론에서 고체이다. 생리활성의 팹티드 또는 단백질의 분자량은 2,000달톤 이상이다. 포화 지방산은 팔미트산, 스테아르산 등과 같이 16∼30개 정도의 탄소원자를 가지는 지방산을 포함한다. 매트릭스는 주상 또는 입상일 수 있다. 비경구 투여제제는 피하 또는 정맥내 투여된 고형주사제(예:이식용 펠렛 또는 정제), 좌약 등으로서 사용될 수 있으며 1주간 이상의 장기간 동안 생리활성 펩티드 또는 단백질을 지속적으로 방출할 수 있다.

Description

서방성 비경구 투여제제 및 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 생리활성 펩티드 또는 단백질 및 포화 지방산의 폴리글리세롤 디에스테르를 함유하는 매트릭스로 구성된 서방성 비경구 투여제제.
  2. 제1항에 있어서, 폴리글리세롤의 평균 중합도가 4인 서방성 비경구 투여제제.
  3. 제1항에 있어서, 포화 지방산이 16∼30개의 탄소원자를 가지는 서방성 비경구 투여제제.
  4. 제1항에 있어서, 폴리글리세롤의 평균 중합도가 4이고, 포화 지방산의 탄소원자수가 16∼30개인 서방성 비경구 투여제제.
  5. 제1항에 있어서, 생리활성 펩티드 또는 단백질이 상기 디에스테르 중에 분산된 서방성 비경구 투여제제.
  6. 제1항에 있어서, 생리활성 펩티드 또는 단백질의 평균 분자량이 2,000달톤 이상인 서방성 비경구 투여제제.
  7. 제1항에 있어서, 생리활성 펩티드 또는 단백질이 인터페론, 인터류킨 또는 인슐린인 서방성 비경구 투여제제.
  8. 제1항에 있어서, 상기 포화 지방산의 탄소원자수가 16∼22개인 서방성 비경구 투여제제.
  9. 제1항에 있어서, 상기 포화 지방산이 팔미트산 또는 스테아르산인 서방성 비경구 투여제제.
  10. 제1항에 있어서, 생리활성 펩티드 또는 단백질의 비율이 매트릭스를 기준으로 0.0001∼50중량%인 서방성 비경구 투여제제.
  11. 제1항에 있어서, 상기 매트릭스가 주상(pillar) 또는 입상(granular)인 서방성 비경구 투여제제.
  12. 제1항에 있어서, 장기 매트릭스가 이식용의 고형주사제인 서방성 비경구 투여제제.
  13. 평균 분자량이 5,000∼1,000,000달톤인 생리활성 펩티드 또는 단백질과, 평균 중합도가 4인 폴리글리세롤과 16∼22개인 탄소원자를 가지는 포화 지방산의 디에스테르를 함유하는 매트릭스로 구성된 제제로서, 매트릭스를 기준으로 하여 0,001∼20중량%의 생리활성 펩티드 또는 단백질이 디에스테르 중에 분산되며, 피하 또는 근육내에 투여할 수 있는 매트릭스로 구성된 서방성 비경구 투여제제.
  14. 제13항에 있어서, 상기 포화 지방산이 팔미트산, 스테아르산 또는 베헨산인 서방성 비경구 투여제제.
  15. 제13항에 있어서, 상기 디에스테르의 융점이 40∼60℃이고, 상기 매트릭스가 실온에서 고체인 서방성 비경구 투여제제.
  16. 제13항에 있어서, 생리활성 펩티드 또는 단백질이 인터페론인 서방성 비경구 투여제제.
  17. 생리활성 펩티드 또는 단백질과 포화 지방산의 용융 또는 연화된 폴리글리세롤 디에스테르를 혼합하고, 용융 혼합물을 성형시킨 서방성 비경구 투여제제의 제조방법.
  18. 제17항에 있어서, 용융 혼합물을 주상 또는 입상으로 성형하는 서방성 비경구 투여제제의 제조방법.
  19. 제17항에 있어서, 건조시킨 분말상의 생리활성 펩티드 또는 단백질을 용융 또는 연화된 디에스테르와 혼합시킨 서방성 비경구 투여제제의 제조방법.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019940020306A 1993-08-26 1994-08-17 서방성비경구투여제제및그제조방법 KR100338400B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP93-235823 1993-08-26
JP23582393 1993-08-26

Publications (2)

Publication Number Publication Date
KR950005329A true KR950005329A (ko) 1995-03-20
KR100338400B1 KR100338400B1 (ko) 2002-11-22

Family

ID=16991792

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940020306A KR100338400B1 (ko) 1993-08-26 1994-08-17 서방성비경구투여제제및그제조방법

Country Status (10)

Country Link
US (2) US5628993A (ko)
EP (1) EP0640336B1 (ko)
JP (1) JPH07112940A (ko)
KR (1) KR100338400B1 (ko)
CN (1) CN1105557C (ko)
AT (1) ATE148625T1 (ko)
CA (1) CA2130868A1 (ko)
DE (1) DE69401691T2 (ko)
DK (1) DK0640336T3 (ko)
TW (1) TW282403B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW282403B (ko) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EP1006935B1 (en) * 1995-06-07 2005-01-26 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA2276450C (en) * 1997-01-02 2013-02-19 Thomas Jefferson University A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
EP1949890A3 (en) 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
CN100370967C (zh) * 1999-06-04 2008-02-27 阿尔萨公司 埋植凝胶组合物及其制备方法
JP2001058955A (ja) * 1999-06-17 2001-03-06 Inst Of Physical & Chemical Res 生理活性ペプチド徐放性製剤
US6740333B2 (en) * 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6967234B2 (en) * 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US7030127B2 (en) * 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
US7034037B2 (en) * 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
JP2005502426A (ja) 2001-09-14 2005-01-27 フランシス ジェイ マーティン 治療剤の徐放のための微細加工ナノ細孔デバイス
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US7005136B2 (en) * 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US7368125B2 (en) * 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
SI2218448T1 (sl) 2002-12-13 2016-01-29 Durect Corporation Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
US6872799B2 (en) * 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US6866860B2 (en) * 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
US20040120981A1 (en) * 2002-12-20 2004-06-24 Aruna Nathan Crosslinked alkyd polyesters for medical applications
CA2529475C (en) 2003-06-27 2012-08-07 Otsuka Pharmaceutical Co., Ltd. Medicament sustained-release particles and method for preparing the same
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
KR100486028B1 (ko) * 2004-04-20 2005-05-03 주식회사 펩트론 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법
ES2432556T3 (es) * 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
KR101351771B1 (ko) 2004-09-17 2014-02-17 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20110059140A1 (en) * 2007-12-21 2011-03-10 Gerhard Winter Extruded rod-shaped devices for controlled release of biological substances to humans and animals
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9532946B2 (en) * 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
IE65045B1 (en) * 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
TW209174B (ko) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IL103275A0 (en) * 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
JPH06219960A (ja) * 1993-01-25 1994-08-09 Takeda Chem Ind Ltd 生理活性ポリペプチド含有組成物の製造法
TW282403B (ko) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
DE69401691D1 (de) 1997-03-20
EP0640336A1 (en) 1995-03-01
ATE148625T1 (de) 1997-02-15
CA2130868A1 (en) 1995-02-27
CN1104488A (zh) 1995-07-05
DE69401691T2 (de) 1997-07-17
DK0640336T3 (da) 1997-04-01
KR100338400B1 (ko) 2002-11-22
US5628993A (en) 1997-05-13
CN1105557C (zh) 2003-04-16
EP0640336B1 (en) 1997-02-05
JPH07112940A (ja) 1995-05-02
US5750100A (en) 1998-05-12
TW282403B (ko) 1996-08-01

Similar Documents

Publication Publication Date Title
KR950005329A (ko) 서방성 비경구 투여제제 및 그 제조방법
EP0661989B1 (en) Sustained-release protein formulations
US6399103B1 (en) Method of producing a sustained-release preparation
US5236704A (en) Controlled release formulation
US4891225A (en) Bioerodible polyanhydrides for controlled drug delivery
AU767632B2 (en) Microencapsulation and sustained release of biologically active agent
CN1165341C (zh) 含有促性腺素的液体制剂
FI80594B (fi) Foerfarande foer framstaellning av en komposition som frigoers kontinuerligt polypeptid, poly(laktidkoglykolid)polymer och foerfarande foer dess framstaellning.
ES2232939T3 (es) Composicion de liberacion sostenida de medicamentos encapsulados en microparticulas de acido hialurico.
KR20010053259A (ko) 생물학적 활성제의 서방성 수송을 위한, 열에 민감하며생분해가능한 히드로겔
KR920002164A (ko) 연속 방출성 약학 조성물
RU94033520A (ru) Впрыскиваемый лецитиновый гель
KR20070046791A (ko) 안정성이 증가된 생체분자-함유 제형
RU2201936C2 (ru) Улучшенный способ получения аддуктов аминов с о-гидроксиальдегидами, являющихся основаниями шиффа, и аддуктный конечный продукт конденсации
US7276251B2 (en) Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
CA2287534C (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
CN102821782A (zh) 促卵泡激素的液体配制品
DE69837997D1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
AU2004251456A1 (en) Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a PLGA matrix
US6255283B1 (en) Use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (TNF)
KR100329336B1 (ko) 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
EP2709595B1 (en) Ifn-beta compositions, preparation methods and uses thereof
Williams et al. Analgesic tolerance to etorphine (M99) and morphine in the mouse
JPH101440A (ja) 徐放性非経口投与製剤およびその製造方法
Rothen‐Weinhold et al. Protein release from poly (ortho ester) extruded rods

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee